KR102137087B1 - 척수성 근위축증을 치료하기 위한 화합물 - Google Patents

척수성 근위축증을 치료하기 위한 화합물 Download PDF

Info

Publication number
KR102137087B1
KR102137087B1 KR1020147025275A KR20147025275A KR102137087B1 KR 102137087 B1 KR102137087 B1 KR 102137087B1 KR 1020147025275 A KR1020147025275 A KR 1020147025275A KR 20147025275 A KR20147025275 A KR 20147025275A KR 102137087 B1 KR102137087 B1 KR 102137087B1
Authority
KR
South Korea
Prior art keywords
pyrido
pyrimidin
methyl
pyrazin
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147025275A
Other languages
English (en)
Korean (ko)
Other versions
KR20140121482A (ko
Inventor
홍얀 퀴
순규 최
아말 다카
개리 미첼 카르프
자나 나라심한
니콜라이 나리쉬킨
안토니 에이 터포프
말라 엘 위트올
엘렌 웰치
매튜 쥐 월
티아늘 양
난징 장
샤오얀 장
신 자오
루크 그린
엠마누엘 피나르드
하산 라트니
Original Assignee
피티씨 테라퓨틱스, 인크.
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48948163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102137087(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 피티씨 테라퓨틱스, 인크., 에프. 호프만-라 로슈 아게 filed Critical 피티씨 테라퓨틱스, 인크.
Priority to KR1020207020788A priority Critical patent/KR102341596B1/ko
Publication of KR20140121482A publication Critical patent/KR20140121482A/ko
Application granted granted Critical
Publication of KR102137087B1 publication Critical patent/KR102137087B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
KR1020147025275A 2012-02-10 2013-02-08 척수성 근위축증을 치료하기 위한 화합물 Active KR102137087B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207020788A KR102341596B1 (ko) 2012-02-10 2013-02-08 척수성 근위축증을 치료하기 위한 화합물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261597523P 2012-02-10 2012-02-10
US61/597,523 2012-02-10
PCT/US2013/025292 WO2013119916A2 (en) 2012-02-10 2013-02-08 Compounds for treating spinal muscular atrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207020788A Division KR102341596B1 (ko) 2012-02-10 2013-02-08 척수성 근위축증을 치료하기 위한 화합물

Publications (2)

Publication Number Publication Date
KR20140121482A KR20140121482A (ko) 2014-10-15
KR102137087B1 true KR102137087B1 (ko) 2020-07-24

Family

ID=48948163

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207020788A Active KR102341596B1 (ko) 2012-02-10 2013-02-08 척수성 근위축증을 치료하기 위한 화합물
KR1020147025275A Active KR102137087B1 (ko) 2012-02-10 2013-02-08 척수성 근위축증을 치료하기 위한 화합물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020207020788A Active KR102341596B1 (ko) 2012-02-10 2013-02-08 척수성 근위축증을 치료하기 위한 화합물

Country Status (29)

Country Link
US (6) US9586955B2 (enExample)
EP (2) EP3406252B1 (enExample)
JP (2) JP6092897B2 (enExample)
KR (2) KR102341596B1 (enExample)
CN (3) CN119528903A (enExample)
AR (1) AR092794A1 (enExample)
AU (2) AU2013216870B2 (enExample)
BR (1) BR112014019750B1 (enExample)
CA (1) CA2863874C (enExample)
CL (1) CL2014002100A1 (enExample)
CO (1) CO7061082A2 (enExample)
CR (1) CR20140376A (enExample)
DK (1) DK2812004T3 (enExample)
EA (2) EA037123B1 (enExample)
EC (1) ECSP14017269A (enExample)
ES (1) ES2697174T3 (enExample)
HU (1) HUE039779T2 (enExample)
IL (2) IL233959A (enExample)
MA (1) MA35920B1 (enExample)
MX (2) MX354074B (enExample)
NZ (1) NZ628186A (enExample)
PE (1) PE20142364A1 (enExample)
PH (2) PH12018501711B1 (enExample)
PL (1) PL2812004T3 (enExample)
SG (2) SG11201404713PA (enExample)
TR (1) TR201813877T4 (enExample)
TW (2) TWI585085B (enExample)
UA (1) UA116981C2 (enExample)
WO (1) WO2013119916A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200093066A (ko) * 2012-02-10 2020-08-04 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10327940B2 (en) 2008-11-09 2019-06-25 3D Systems, Inc. Spiral brace
USRE47689E1 (en) 2011-12-30 2019-11-05 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
PL2809322T3 (pl) 2012-01-26 2019-11-29 Ptc Therapeutics Inc Związki do leczenia zaniku mięśni pochodzenia rdzeniowego
CA2865957C (en) 2012-03-01 2020-02-11 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
KR102109992B1 (ko) 2012-03-23 2020-05-13 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
US10987370B2 (en) * 2012-12-24 2021-04-27 Ramot At Tel-Aviv University Ltd. Methods of inducing read-through of a nonsense mutation associated with ataxia telangiectasia, Rett syndrome or spinal muscular atrophy by erythromycin or azithromycin
BR112015032718A2 (pt) 2013-08-19 2019-09-17 Hoffmann La Roche composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
WO2015105657A1 (en) * 2013-12-19 2015-07-16 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
PL3663296T3 (pl) * 2014-05-15 2023-08-07 F. Hoffmann-La Roche Ag Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
ES2879809T3 (es) * 2014-11-01 2021-11-23 Shanghai Fochon Pharmaceutical Co Ltd Ciertos inhibidores de proteínas quinasas
WO2016111896A1 (en) * 2015-01-05 2016-07-14 Sikorsky Aircraft Corporation Integrated vibration damper for additively manufactured structure and method
JP6749343B2 (ja) * 2015-05-20 2020-09-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するための化合物
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
EP3359685A1 (en) 2015-10-09 2018-08-15 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
CN108289959B (zh) 2015-11-12 2021-07-16 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的组合物
KR20180081520A (ko) * 2015-11-12 2018-07-16 에프. 호프만-라 로슈 아게 근위축성 측삭 경화증의 치료를 위한 화합물
HRP20201522T1 (hr) 2015-12-09 2020-12-11 Cadent Therapeutics, Inc. Heteroaromatski nmda receptor modulatori i njihove uporabe
EA201800367A1 (ru) 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения болезни хантингтона
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
US11083745B2 (en) 2015-12-14 2021-08-10 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome
CN108473510B (zh) * 2016-04-28 2021-10-29 豪夫迈·罗氏有限公司 制备2-吡唑并[1,5-a]吡嗪-2-基吡啶并[1,2-a]嘧啶-4-酮的方法
EP3471779A4 (en) 2016-06-16 2020-07-08 Ionis Pharmaceuticals, Inc. COMBINATIONS FOR MODULATING SMN EXPRESSION
US11702646B2 (en) 2016-11-28 2023-07-18 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
EP3558318B1 (en) 2016-12-22 2023-12-20 Novartis AG Nmda receptor modulators and uses thereof
KR20200033249A (ko) 2017-06-05 2020-03-27 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물
JP2020523365A (ja) 2017-06-14 2020-08-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａスプライシングを改変する方法
CA3067591A1 (en) * 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
CN111499615B (zh) 2017-08-04 2024-02-02 斯基霍克疗法公司 用于调节剪接的方法和组合物
SMT202400071T1 (it) 2017-08-25 2024-03-13 Stoke Therapeutics Inc Oligomeri antisenso per il trattamento di condizioni e malattie
MX2020002711A (es) * 2017-09-22 2020-07-20 Hoffmann La Roche Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.
HRP20250322T1 (hr) 2017-10-23 2025-06-06 Stoke Therapeutics, Inc. Protusmisleni oligomeri, namijenjeni liječenju stanja i bolesti uzrokovanih raspadanjem rna posredovanim besmislenim mutacijama
US12103926B2 (en) 2018-03-27 2024-10-01 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
JP2021523227A (ja) 2018-05-04 2021-09-02 ストーク セラピューティクス，インク． コレステリルエステル蓄積症の処置のための方法及び組成物
SG11202013088YA (en) 2018-06-27 2021-02-25 Reborna Biosciences Inc Prophylactic or therapeutic agent for spinal muscular atrophy
EA202092899A1 (ru) 2018-06-27 2021-05-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Гетероарильные соединения для лечения болезни гентингтона
BR112020026545A2 (pt) 2018-06-27 2021-03-23 Ptc Therapeutics, Inc. Compostos heterocíclicos e de heteroarila para o tratamento da doença de huntington
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
CU24647B1 (es) 2018-08-03 2023-02-13 Cadent Therapeutics Inc Moduladores del receptor nmda heteroaromático
KR20210042123A (ko) * 2018-08-07 2021-04-16 더 칠드런스 호스피탈 오브 필라델피아 유전자 발현의 선택적 스플라이싱 조절 및 치료 방법
CN114007613A (zh) 2019-02-05 2022-02-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
JP7603595B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
US12492214B2 (en) 2019-07-31 2025-12-09 Assia Chemical Industries Ltd. Solid state forms of Risdiplam and process for preparation thereof
CN110540535B (zh) * 2019-10-23 2020-07-31 上海再启生物技术有限公司 适合放大制备4-(6-氨基吡啶-3-基)取代哌啶的工艺方法
CN111116576A (zh) * 2019-12-01 2020-05-08 北京师范大学 一种喹嗪酮类化合物及其制备方法
BR112022010561A2 (pt) 2019-12-02 2022-11-16 Storm Therapeutics Ltd Compostos poli-heterocíclicos como inibidores de mettl3
MX2022009025A (es) 2020-01-28 2022-10-07 Protego Biopharma Inc Compuestos, composiciones y métodos para estabilizar la transtiretina e inhibir el plegamiento incorrecto de la transtiretina.
EP4103717A4 (en) * 2020-02-12 2024-02-28 The Children's Hospital of Philadelphia Compositions and methods for inducible alternative splicing regulation of gene expression
EP4110775A1 (en) 2020-02-28 2023-01-04 Remix Therapeutics Inc. Thiophenyl derivatives useful for modulating nucleic acid splicing
MX2022010634A (es) 2020-02-28 2023-01-19 Remix Therapeutics Inc Derivados de piridazina para modular el empalme de acidos nucleicos.
JP7446443B2 (ja) 2020-02-28 2024-03-08 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｓｍｎ２を調節するための化合物及び方法
JP7736700B2 (ja) 2020-02-28 2025-09-09 リミックス セラピューティクス インコーポレイテッド 複素環アミド及びスプライシングを調節するためのその使用
AU2021228285A1 (en) 2020-02-28 2022-09-29 Remix Therapeutics Inc. Compounds and methods for modulating splicing
TW202208344A (zh) 2020-04-08 2022-03-01 美商雷密克斯醫療公司 調節剪接之化合物及方法
BR112022020418A2 (pt) 2020-04-08 2023-05-02 Remix Therapeutics Inc Compostos e métodos para modulação de splicing
CA3173647A1 (en) 2020-05-11 2021-11-18 Isabel AZNAREZ Opa1 antisense oligomers for treatment of conditions and diseases
WO2022006543A1 (en) 2020-07-02 2022-01-06 Remix Therapeutics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
WO2022006550A1 (en) 2020-07-02 2022-01-06 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
WO2022070071A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
KR20230157367A (ko) 2021-03-17 2023-11-16 에프. 호프만-라 로슈 아게 신규 티아졸로피리미디논 유도체
TW202321206A (zh) 2021-07-28 2023-06-01 美商普羅泰戈生物製藥股份有限公司 轉甲狀腺素蛋白穩定化合物
WO2023034827A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US20240400584A1 (en) 2021-08-30 2024-12-05 Remix Therapeutics Inc. Compounds and methods for modulating splicing
PE20241764A1 (es) 2021-08-30 2024-08-28 Remix Therapeutics Inc Compuestos y metodos para modular el empalme
WO2023034836A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
TW202319047A (zh) 2021-08-30 2023-05-16 美商雷密克斯醫療公司 調節剪接之化合物及用途
EP4416141A1 (en) 2021-10-13 2024-08-21 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
WO2023064879A1 (en) 2021-10-13 2023-04-20 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
US20250109140A1 (en) 2022-01-05 2025-04-03 Remix Theraputics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
US20250092065A1 (en) 2022-01-05 2025-03-20 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
US20250326748A1 (en) 2022-01-05 2025-10-23 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
AU2024286618A1 (en) * 2023-06-09 2025-10-30 F. Hoffmann-La Roche Ag Inducible gene expression system
CN117263936B (zh) * 2023-11-21 2024-02-23 中国中医科学院医学实验中心 一种咪唑并[1, 2-a]吡啶衍生物及其制备方法和在中枢神经系统渗透性HDAC6抑制药物中的应用
WO2025233837A1 (en) 2024-05-07 2025-11-13 Takeda Pharmaceutical Company Limited 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050245A1 (en) * 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558618A (en) 1968-04-01 1971-01-26 Dow Chemical Co Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
US4342870A (en) * 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
JPS56150091A (en) * 1980-03-28 1981-11-20 Janssen Pharmaceutica Nv 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture
US5089633A (en) 1987-04-28 1992-02-18 Georgia Tech Research Corporation Substituted isocoumarins
US5726182A (en) 1990-05-02 1998-03-10 Abbott Laboratories Quinolizinone type compounds
AU4231293A (en) * 1992-05-13 1993-12-13 E.I. Du Pont De Nemours And Company Substituted pyrido(1,2-A)pyrimidinone derivatives as fungicides
WO1996039407A1 (en) 1995-06-06 1996-12-12 Abbott Laboratories Quinolizinone type compounds
US5869500A (en) 1996-12-13 1999-02-09 Hoffmann-La Roche Inc. Pyridone compounds useful in treating Alzheimer's disease
US6630488B1 (en) * 1998-09-21 2003-10-07 Biochem Pharma, Inc. Quinolizinones as integrin inhibitors
DE60024861T2 (de) * 1999-10-28 2006-07-06 Trine Pharmaceuticals, Inc., Waltham Pumpeninhibitoren zur freisetzung von medikamenten
CN1891699A (zh) * 2000-01-24 2007-01-10 基纳西亚股份有限公司 用于治疗的吗啉代基取代的化合物
CA2445697A1 (en) 2001-04-26 2002-11-07 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
DE60236322D1 (de) 2001-12-07 2010-06-17 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
GB0205281D0 (en) 2002-03-06 2002-04-17 Novartis Ag Organic compounds
ATE548354T1 (de) 2002-07-24 2012-03-15 Ptc Therapeutics Inc Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
ATE458735T1 (de) * 2003-06-20 2010-03-15 Novartis Vaccines & Diagnostic Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs
BRPI0510560A (pt) 2004-05-04 2007-11-20 Warner Lambert Co pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
CN101146798A (zh) 2005-01-21 2008-03-19 詹森药业有限公司 用作雌激素受体调节剂的新的杂环苯并[c]色烯衍生物
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
WO2008013997A2 (en) 2006-07-27 2008-01-31 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
US8932818B2 (en) 2008-08-13 2015-01-13 Ptc Therapeutics, Inc. Screening assays for compounds that modulate programmed ribosomal frameshifting
US8754220B2 (en) * 2009-11-20 2014-06-17 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide M1 receptor positive allosteric modulators
CA2786329A1 (en) * 2010-01-13 2011-07-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti - infective pyrido (1,2-a) pyrimidines
USRE47689E1 (en) 2011-12-30 2019-11-05 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
PL2809322T3 (pl) 2012-01-26 2019-11-29 Ptc Therapeutics Inc Związki do leczenia zaniku mięśni pochodzenia rdzeniowego
CN119528903A (zh) * 2012-02-10 2025-02-28 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
CA2865957C (en) 2012-03-01 2020-02-11 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
KR102109992B1 (ko) 2012-03-23 2020-05-13 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
PL3663296T3 (pl) 2014-05-15 2023-08-07 F. Hoffmann-La Roche Ag Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni
JP6749343B2 (ja) 2015-05-20 2020-09-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するための化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050245A1 (en) * 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Jareck et al., Human Molecular Genetics, 2005, 14(14), pp.2003-2018 (2005.6.8.)*
Peng et al., J. Med. Chem., 2011, 54, 7729-7733 (2011.09.29.)*

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200093066A (ko) * 2012-02-10 2020-08-04 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
KR102341596B1 (ko) * 2012-02-10 2021-12-21 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물

Also Published As

Publication number Publication date
JP2017122097A (ja) 2017-07-13
HUE039779T2 (hu) 2019-02-28
EA029542B1 (ru) 2018-04-30
IL254045B (en) 2019-05-30
US20240067646A1 (en) 2024-02-29
EA201792465A1 (ru) 2018-08-31
BR112014019750A8 (pt) 2018-01-16
MX2022011699A (es) 2022-11-09
AR092794A1 (es) 2015-05-06
JP6363744B2 (ja) 2018-07-25
EP3406252A1 (en) 2018-11-28
KR20200093066A (ko) 2020-08-04
PE20142364A1 (es) 2015-01-10
IL254045A0 (en) 2017-10-31
AU2013216870B2 (en) 2017-07-20
PH12018501711A1 (en) 2019-09-23
TWI585085B (zh) 2017-06-01
AU2013216870A1 (en) 2014-08-28
IL233959A (en) 2017-11-30
EP2812004B1 (en) 2018-06-27
EP2812004A4 (en) 2015-11-11
NZ628186A (en) 2016-03-31
CN104349777B (zh) 2018-05-01
US20180105526A1 (en) 2018-04-19
EP2812004A2 (en) 2014-12-17
US20170129885A1 (en) 2017-05-11
CO7061082A2 (es) 2014-09-19
BR112014019750B1 (pt) 2020-03-03
MX354074B (es) 2018-02-12
US9879007B2 (en) 2018-01-30
PH12014501786A1 (en) 2014-11-10
AU2017204248B2 (en) 2019-05-30
PH12018501711B1 (en) 2023-05-05
US20150005289A1 (en) 2015-01-01
ECSP14017269A (es) 2015-09-30
EP3406252B1 (en) 2020-05-13
TW201336842A (zh) 2013-09-16
CR20140376A (es) 2015-01-23
IL233959A0 (en) 2014-09-30
JP6092897B2 (ja) 2017-03-08
SG10201609188WA (en) 2016-12-29
US20190375750A1 (en) 2019-12-12
CN108299314A (zh) 2018-07-20
MX2014009696A (es) 2015-01-14
UA116981C2 (uk) 2018-06-11
TW201722942A (zh) 2017-07-01
JP2015508075A (ja) 2015-03-16
WO2013119916A3 (en) 2013-10-24
CA2863874C (en) 2021-02-16
KR20140121482A (ko) 2014-10-15
TWI629274B (zh) 2018-07-11
US20210276999A1 (en) 2021-09-09
ES2697174T3 (es) 2019-01-22
DK2812004T3 (en) 2018-10-15
CA2863874A1 (en) 2013-08-15
CL2014002100A1 (es) 2015-10-23
TR201813877T4 (tr) 2018-11-21
AU2017204248A1 (en) 2017-07-13
US11753407B2 (en) 2023-09-12
WO2013119916A2 (en) 2013-08-15
EA201491505A1 (ru) 2015-01-30
HK1202077A1 (en) 2015-09-18
CN119528903A (zh) 2025-02-28
BR112014019750A2 (pt) 2017-06-20
MA35920B1 (fr) 2014-12-01
PL2812004T3 (pl) 2019-01-31
KR102341596B1 (ko) 2021-12-21
CN104349777A (zh) 2015-02-11
US10851101B2 (en) 2020-12-01
US9586955B2 (en) 2017-03-07
SG11201404713PA (en) 2014-09-26
EA037123B1 (ru) 2021-02-09
CN108299314B (zh) 2024-11-26
PH12014501786B1 (en) 2014-11-10

Similar Documents

Publication Publication Date Title
KR102137087B1 (ko) 척수성 근위축증을 치료하기 위한 화합물
KR102057351B1 (ko) 척수성 근위축증을 치료하기 위한 화합물
KR102064624B1 (ko) 척수성 근위축증을 치료하기 위한 화합물
KR102099997B1 (ko) 척수성 근위축증을 치료하기 위한 화합물
KR102109992B1 (ko) 척수성 근위축증을 치료하기 위한 화합물
HK40005163B (en) Compounds for treating spinal muscular atrophy
HK40005163A (en) Compounds for treating spinal muscular atrophy
HK1202077B (en) Compounds for treating spinal muscular atrophy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140905

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180125

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190531

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200129

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200417

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200716

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200717

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200720

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230622

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240625

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20250630

Start annual number: 6

End annual number: 6